{"id":"W2759277150","doi":"10.1186/s13045-017-0527-7","title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharma; Genentech; AOP Orphan; CTI Biopharma; Incyte; Baxalta; Ariad Pharmaceuticals; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Hazard ratio; Randomized controlled trial; International Prognostic Scoring System; Clinical endpoint; Anemia; Hematology; Placebo; Survival analysis; Proportional hazards model; Clinical trial; Subgroup analysis; Surgery; Confidence interval; Bone marrow; Myelodysplastic syndromes; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002854652,0.000229512,0.001479169,0.0002621551,0.0002600001,0.00002263266,0.0001297213,0.000218362,0.00003745936],"category_scores_gemma":[0.0002625536,0.0001458545,0.000138364,0.00005641254,0.0002584569,0.0001347446,0.0000599662,0.0002232823,0.000001530474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001517476,"about_ca_system_score_gemma":0.000253261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003207506,"about_ca_topic_score_gemma":0.0003646961,"domain_scores_codex":[0.9984357,0.0001176837,0.0006953141,0.0002389272,0.0001743969,0.0003379592],"domain_scores_gemma":[0.9977717,0.0004001868,0.0009886815,0.0002487454,0.0003947585,0.0001958606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003991577,0.001788524,0.989266,0.00007648193,0.0008727773,0.0006930882,0.0001562075,0.000001069031,0.00009874493,0.0003934639,0.0001662262,0.002495863],"study_design_scores_gemma":[0.02005192,0.01403807,0.9607309,0.0002559944,0.0009152264,0.001207351,0.00006540061,0.000008727417,0.002265432,0.00006142451,0.0002805982,0.0001189848],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959515,0.0004370092,0.00003315945,0.00234146,0.0001446388,0.0005552035,0.00001297428,0.000006659825,0.000517421],"genre_scores_gemma":[0.9982116,0.0001878463,0.001124109,0.0002279165,0.00007773624,0.00005363391,0.0000203175,0.00001993672,0.00007695048],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02853511,"threshold_uncertainty_score":0.5947773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0497649413758295,"score_gpt":0.3819046456399105,"score_spread":0.332139704264081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}